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Results: Thirty-nine countries have agreed to participate (original target 22) and
29 countries have sent their preliminary data. Initial analysis suggests a relative
paucity of CF patients in Europe who are over 35 years of age. Further analyses
are underway to determine the reasons.
Conclusions: The project is on track to meet its milestones despite an unexpected
rise in the take up from countries outside the European Union.
R18 OF MICE AND MEN: EARLY AIRWAY WALL DISEASE IN CYSTIC
FIBROSIS
A. Bush. Professor of Paediatric Respirology, Imperial College, London, United
Kingdom
The baby with cystic ﬁbrosis (CF) has essentially normal lungs at birth, but at
death has extensive airway wall destruction. This has been assumed to be secondary
to infection and inﬂammation, but recent evidence has challenged this paradigm,
and suggested that there may be a component of a speciﬁc CF related airway
wall disease, independent of infection and inﬂammation. We initially showed that
unscreened CF babies have airway obstruction at diagnosis, independent of any
previous or present respiratory symptoms, signs and positive cultures, and this
persists for six months, even despite intensive therapy [Lancet. 2001; 358:1964−5;
Am J Respir Crit Care Med. 2002; 166: 1350−7 & 2004; 169: 928−33]. Recent
data (Koslowska, unpublished) shows that even preschool children have CF related
airﬂow obstruction, independent of infection. We explored this using endobronchial
biopsy in CF children. We established the technique was safe [Pediatr Pulmonol.
2006; 41: 1021−4], and yielded acceptable material [Chest. 2007; 131: 1710−7];
we then showed that there were increased concentrations of elastin, glycosamino-
glycans and collagen in CF BALF compared to controls, and each correlated with
elastase activity, MMP-9 and neutrophil concentration. Both elastin concentration
and MMP-9:TIMP-1 ratio, correlated negatively with FEV1 (r = −0.45, p< 0.05
and r = −0.47, p< 0.05 respectively). Median reticular basement membrane (RBM)
thickness was greater in CF (5.9mm) than controls (4.0mm, p< 0.01), and corre-
lated with transforming growth factor-b1 (TGF-b1) concentration (r = 0.53, p = 0.01,
but not with FEV1. These data suggested there are two forms of airway remodelling
in CF children: ﬁrstly, matrix breakdown which correlates with proteases and pul-
monary function, and secondly RBM thickening, related to TGF-b1 concentration
[Hilliard T, Thorax in press]. We supplemented these observations in the CF mouse
nose [Hilliard T, Am J Resp Cell Mol Biol in press] by performing nasal lavage and
serial coronal section through the nasal tissue of adult CF and wild type mice raised
under normal housing conditions. Nasal tissue was also obtained from day 17 em-
bryos and newborn pups. Detailed histological examination of the nasal cavity was
performed. Bacterial culture, cell count and Macrophage Inﬂammatory Protein-2
(MIP-2) concentration were assessed in nasal lavage ﬂuid. Signiﬁcantly thickened
respiratory epithelium and increased mucous cell density was found in adult CF
mice of both mutations compared to wild type animals. There were no differences in
bacterial growth, cell count or MIP-2 concentrations. Thus, there are structural and
inﬂammatory changes in the nasal mucosa in adult CF mice, not present perinatally,
that develop in the absence of increased lumenal bacterial infection. Hence evidence
from both mice and men suggests there may be a CF-related airway wall disease,
independant of infection, which may represent a novel therapeutic target.
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L.J.V. Galietta. Istituto Giannina Gaslini, Genova, Italy
Pharmacotherapy of cystic ﬁbrosis (CF) basic defect, i.e. defective Cl− secretion,
requires a good knowledge of the loss of function mechanism associated with each
CF mutation. Indeed, CF mutations are typically grouped in ﬁve classes according to
the mechanism of action. Pharmacological approaches aimed directly at the CFTR
protein have been designed for three classes of mutations. For class I, consisting in
stop codon mutations, aminoglycoside antibiotics or the new agent PTC124 allow
to produce an almost normal CFTR by a read-through mechanism. For class II,
which includes F508del, pharmacological chaperones (also known as correctors)
can be used to improve the maturation of the mutant protein. Finally, class III
mutations, which cause a severe decrease in CFTR channel activity, can be treated
with potentiators, small molecules able to restore the normal channel gating.
The speciﬁc mechanism of each compound will clearly require in the future a
tailored use dependent on the CF patient genotype. However, the choice of a
particular pharmacological approach will not only depend on the CFTR genotype
but will need to consider also the inﬂuence of other genetic factors. For example,
the efﬁcacy of PTC124 and of other similar drugs affecting read-through of stop
codon mutations may be limited by nonsense-mediated mRNA decay, a process
that seems to be characterized by variability among individuals. On the other hand,
pharmacological chaperones identiﬁed so far for F508del probably interact with
cell proteins involved in CFTR biogenesis, intracellular transport, and degradation.
Accordingly, individual variability in CFTR protein handling due to genetic factors
may also affect the therapeutic outcome of F508del correctors.
Restoration of Cl− secretion in CF patients may be also obtained with the so-
called bypassing approach, i.e. by stimulating the activity of Ca2+-dependent Cl−
channels. Denufosol, a drug that is now tested in clinical studies, activates Ca2+-
dependent Cl− channels through interaction with the P2Y2 purinergic receptor. Also
in this case, individual variability may affect the extent of therapeutic intervention.
Indeed, it has been shown that polymorphisms in the P2Y2 receptor inﬂuence the
intracellular Ca2+ response triggered by purinergic agonists and therefore the extent
of Cl− secretion.
As for other human diseases, the inﬂuence of genetic variability will need to be
considered to optimize drug therapy in CF. This will be particularly important in
the design and evaluation of clinical studies testing the efﬁcacy of new drugs.
R20 FROM BENCH TO BEDSIDE: MODULATION OF AIRWAY
INFLAMMATION IN CYSTIC FIBROSIS
F. Ratjen. Division of Respiratory Medicine, The Hospital for Sick Children,
Toronto, Canada
Neutrophilic airway inﬂammation is a characteristic feature of cystic ﬁbrosis (CF)
lung disease. There is ongoing controversy whether the CFTR mutation itself causes
a pro-inﬂammatory milieu in the airways, which would imply that inﬂammation
can precede infection, or whether inﬂammation is always secondary to infection.
Studies in cell culture have yielded conﬂicting results. While initial studies showed
increased NFúB activation and IL-8 production in unstimulated CF epithelial cells,
others found a higher inﬂammatory response only after infection with P. aeruginosa.
Animal models of CF do not exhibit the phenotype of chronic infection, but
recent studies suggest that the response to infection is upregulated in CF mice.
Furthermore sterile CF airways transplanted into SCID mice demonstrate higher
IL-8 concentrations and luminal invasion of neutrophils, which would support the
concept of a pro-inﬂammatory milieu in CF. While it is important to clarify this,
there is sufﬁcient evidence that airway inﬂammation is present in almost all patients
with pulmonary manifestations of the disease. Since the presence of inﬂammation
has been shown to be a risk factor for subsequent lung function decline, reliable tests
to monitor airway inﬂammation in the clinic are urgently needed. Induced sputum
is currently being assessed as a clinical and research tool, but unfortunately is not
feasible in young children. While nonspeciﬁc treatment approaches that decrease
infection or improve clearance of airway secretions were found to positively affect
airway inﬂammation, speciﬁc anti-inﬂammatory treatment strategies have been less
successful to date. A number of studies have now provided evidence that potent
inhibitors of airway inﬂammation may potentially have a detrimental effect by
promoting airway infection. This stresses the need to develop a better understanding
of the factors regulating inﬂammation in the CF lung to develop better targeted
treatment strategies in the future.
R21 EXPLOITING GENOMICS TO DEVELOP NEW ANTIBIOTICS AND
VACCINES AGAINST CF-RELATED PATHOGENS
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Despite the development of potent antibiotics, P. aeruginosa and S. aureus still
cause most of the morbidity and mortality in patients with cystic ﬁbrosis (CF).
Multiple courses of antibiotics in these patients have increased the resistance of the
pathogens to many antibiotics and multi-resistant transmissible epidemic P. aerugi-
nosa and methicillin-resistant S. aureus (MRSA) strains have been identiﬁed in CF
centers. Sadly, the development of effective chemotherapeutic agents against these
pathogens has ceased in the last decade. Thus, alternative approaches to develop
antimicrobial agents with new modes of action and potent vaccines are needed.
Genome sequencing and advances in post-genomic technologies such as functional
genomics through antisense technology, insertion mutagenesis and bioinformatics
analysis has opened the way for large-scale screening of bacterial targets for new
antimicrobials. Integrated genomics, devised to screen whole bacterial genomes and
to identify targets, different from those identiﬁed using conventional approaches
can be used today. Using such techniques, key bacterial virulence determinants,
expressed under host/pathogen conditions, providing essential functions for bacterial
growth and pathogenesis in vivo, can be identiﬁed. To ensure broad protection,
sequence variability and adaptive mechanisms, leading to gene mutations and
homologous recombination have to be taken into account. Comparative genomic
analysis is now considered as critical to provide a solid rationale to further proceed
towards the development of antibacterials with global relevance.
